However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers, and has been ...

AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...

Immune-mediated rash or dermatitis occurred in 1.8% (34/1889 ... The safety and effectiveness of IMFINZI has not been established in pediatric patients. IMFINZI® (durvalumab), as a single ...

Advances in systemic treatment for limited-stage SCLC have not progressed over the decades. However, more recent studies have suggested that adjuvant therapy with a high-affinity human IgG1 monoclonal ...

Immune-mediated rash or dermatitis occurred in 1.8% (34/ ... Europe and Asia. IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction ...

Consolidation durvalumab is underutilized in unresectable stage III NSCLC, with only 61.5% of eligible patients receiving it post-cCRT. Patients receiving durvalumab after cCRT show improved ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

Common skin rashes in children can be easily identifiable, such as those caused by diaper rash or an insect bite. Pictures of skin rashes can help you to recognize ringworm, measles, and more when you ...